Abstract
The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 46314632 |
| Number of pages | 1 |
| Journal | Clinical Cancer Research |
| Volume | 24 |
| Issue number | 19 |
| DOIs | |
| State | Published - Oct 1 2018 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2018 American Association for Cancer Research.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS